| Carbapenemase-producing Pseudomonas aeruginosa –an emerging challenge FC Tenover, DP Nicolau, CM Gill Emerging Microbes & Infections 11 (1), 811-814, 2022 | 98 | 2022 |
| The ERACE-PA Global Surveillance Program: ceftolozane/tazobactam and ceftazidime/avibactam in vitro activity against a global collection of carbapenem-resistant Pseudomonas … CM Gill, E Aktaþ, W Alfouzan, L Bourassa, A Brink, CAD Burnham, ... European journal of clinical microbiology & infectious diseases 40, 2533-2541, 2021 | 55 | 2021 |
| Evaluation of the EDTA-Modified Carbapenem Inactivation Method for Detecting Metallo-β-Lactamase-Producing Pseudomonas aeruginosa CM Gill, MJ Lasko, TE Asempa, DP Nicolau Journal of Clinical Microbiology 58 (6), 10.1128/jcm. 02015-19, 2020 | 39 | 2020 |
| T2 Candida versus beta-D-glucan to facilitate antifungal discontinuation in the intensive care unit CM Gill, RM Kenney, L Hencken, ME Mlynarek, GJ Alangaden, ... Diagnostic microbiology and infectious disease 95 (2), 162-165, 2019 | 24 | 2019 |
| A review of nonantibiotic agents to prevent urinary tract infections in older women CM Gill, MSA Hughes, KL LaPlante Journal of the American Medical Directors Association 21 (1), 46-54, 2020 | 23 | 2020 |
| Evaluation of the Xpert Carba-R NxG assay for detection of carbapenemase genes in a global challenge set of Pseudomonas aeruginosa isolates CM Gill, TE Asempa, IA Tickler, C dela Cruz, FC Tenover, DP Nicolau Journal of Clinical Microbiology 58 (12), 10.1128/jcm. 01098-20, 2020 | 17 | 2020 |
| Development and application of a pragmatic algorithm to guide definitive carbapenemase testing to identify carbapenemase-producing Pseudomonas aeruginosa CM Gill, TE Asempa, DP Nicolau Antibiotics 9 (11), 738, 2020 | 13 | 2020 |
| EDTA-modified carbapenem inactivation method (eCIM) for detecting IMP Metallo-β-lactamase–producing Pseudomonas aeruginosa: an assessment of increasing … MJ Lasko, CM Gill, TE Asempa, DP Nicolau BMC microbiology 20, 1-5, 2020 | 12 | 2020 |
| Cefiderocol Pharmacokinetics in a Patient Receiving Continuous Venovenous Hemodiafiltration E Kobic, CM Gill, AB Mochon, NP Nicolasora, DP Nicolau Open Forum Infectious Diseases 8 (7), ofab252, 2021 | 11 | 2021 |
| Pharmacologic optimization of antibiotics for Gram-negative infections CM Gill, DP Nicolau Current opinion in infectious diseases 32 (6), 647-655, 2019 | 11 | 2019 |
| Human-simulated antimicrobial regimens in animal models: transparency and validation are imperative CM Gill, TE Asempa, DP Nicolau Antimicrobial Agents and Chemotherapy 64 (8), 10.1128/aac. 00594-20, 2020 | 10 | 2020 |
| Discrepancy in sustained efficacy and resistance emergence under human-simulated exposure of cefiderocol against Stenotrophomonas maltophilia between in vitro chemostat and in … CM Gill, K Abdelraouf, M Oota, R Nakamura, M Kuroiwa, Y Gahara, ... Journal of Antimicrobial Chemotherapy 76 (10), 2615-2621, 2021 | 9 | 2021 |
| In vivo activity of WCK 4282 (high-dose cefepime/tazobactam) against serine β-lactamase-producing Enterobacterales and Pseudomonas aeruginosa in the … CM Gill, K Abdelraouf, DP Nicolau Journal of Antimicrobial Chemotherapy 76 (4), 993-1000, 2021 | 9 | 2021 |
| Efficacy of human-simulated exposures of meropenem/vaborbactam and meropenem against OXA-48 β-lactamase-producing Enterobacterales in the neutropenic murine thigh infection model CM Gill, TE Asempa, DP Nicolau Journal of Antimicrobial Chemotherapy 76 (1), 184-188, 2021 | 9 | 2021 |
| In vivo efficacy & resistance prevention of cefiderocol in combination with ceftazidime/avibactam, ampicillin/sulbactam or meropenem using human-simulated regimens versus … CM Gill, D Santini, M Takemura, C Longshaw, Y Yamano, R Echols, ... Journal of Antimicrobial Chemotherapy 78 (4), 983-990, 2023 | 8 | 2023 |
| Elevated MICs of susceptible antipseudomonal cephalosporins in non-carbapenemase-producing, carbapenem-resistant Pseudomonas aeruginosa: implications for dose optimization CM Gill, E Aktaş, W Alfouzan, L Bourassa, A Brink, CAD Burnham, ... Antimicrobial agents and chemotherapy 65 (11), 10.1128/aac. 01204-21, 2021 | 8 | 2021 |
| Carbapenem-resistant Pseudomonas aeruginosa: an assessment of frequency of isolation from ICU versus non-ICU, phenotypic and genotypic profiles in a … CM Gill, DP Nicolau, ERACE-PA Global Study Group Antimicrobial Resistance & Infection Control 11 (1), 146, 2022 | 7 | 2022 |
| In vivo translational assessment of the GES genotype on the killing profile of ceftazidime, ceftazidime/avibactam and meropenem against Pseudomonas aeruginosa CM Gill, A Oliver, PA Fraile-Ribot, DP Nicolau Journal of Antimicrobial Chemotherapy 77 (10), 2803-2808, 2022 | 7 | 2022 |
| Phenotypes, genotypes and breakpoints: an assessment of β-lactam/β-lactamase inhibitor combinations against OXA-48 TE Asempa, AK Kois, CM Gill, DP Nicolau Journal of Antimicrobial Chemotherapy 78 (3), 636-645, 2023 | 6 | 2023 |
| Phenotypic and genotypic profile of ceftolozane/tazobactam-non-susceptible, carbapenem-resistant Pseudomonas aeruginosa CM Gill, DP Nicolau Journal of Antimicrobial Chemotherapy 78 (1), 252-256, 2023 | 6 | 2023 |
